Please ensure Javascript is enabled for purposes of website accessibility

Why Bluebird Bio Stock Is Crashing Today

By Keith Speights – Aug 9, 2021 at 12:38PM

Key Points

  • Bluebird disclosed in its Q2 update that its phase 3 study evaluating eli-cel in treating CALD has been placed on clinical hold by the FDA.
  • The company also stated that it will withdraw from the European market because of challenges obtaining market access and desired pricing for Zyngeglo.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker had a double whammy of bad news.

What happened

Shares of Bluebird Bio (BLUE -2.90%) were crashing 23.3% lower as of 12:18 p.m. EDT on Monday. The big decline came after the company announced two negative developments in its second-quarter update.

Bluebird said that the U.S. Food and Drug Administration (FDA) has placed a phase 3 study featuring eli-cel (also known as Lenti-D) on clinical hold. The company also stated that it plans to focus only on the U.S. market with its severe genetic disease products and pull out of the European market. 

So what

With Bluebird's double whammy this morning, it's not surprising that the biotech stock tanked. But just how bad is the news for the company?

A person wearing a white coat with a stethoscope holding a hand up as if to halt someone.

Image source: Getty Images.

The FDA clinical hold for eli-cel affects only the phase 3 study targeting cerebral adrenoleukodystrophy (CALD). Bluebird doesn't expect this clinical hold to spill over to its studies of eli-cel that target other indications such as beta-thalassemia, sickle cell disease, or cancer.

One patient who was treated with eli-cel over a year ago in the late-stage ALD-104 clinical trial reported a serious adverse reaction. Bluebird didn't provide much detail on this reaction but did state that the evidence points to its Lenti-D lentiviral vector as a potential contributing factor.

The company's decision to focus only on the U.S. was a direct result of its uphill battle securing market access and the pricing it wanted for Zynteglo in Europe. Andrew Obenshain, president of Bluebird's severe genetic diseases business, said, "While European regulators have been innovative partners in supporting accelerated regulatory paths for these therapies, European payers have not yet evolved their approach to gene therapy in a way that can recognize the innovation and the expected life-long benefit of these products."

The U.S. certainly presents a larger market opportunity for Bluebird. However, the failure to gain traction in Europe is still a big blow that limits the company's growth prospects.

Now what

Bluebird intends to work with regulators with the goal to have the clinical hold for eli-cel lifted as soon as possible. The biotech company still thinks that it will be able to complete the U.S. regulatory submissions for the drug in treating beta-thalassemia and CALD this year.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Bluebird Bio. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bluebird Bio Stock Quote
Bluebird Bio
BLUE
$7.37 (-2.90%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.